



Midwest Cardiovascular Research Foundation

Fall 2006

Volume 4, Issue 4

MCRF's Holiday Open House


On November 29, 2006 MCRF hosted it's first Holiday Open House. Over one hundred people including neighbors, friends, industry representatives, health care providers and other professional visited MCRF's headquarters at 1622 E. Lombard Street, in Davenport, Iowa. "The support that MCRF has seen in a couple of hours was overwhelming", Dr. Shammas, Research Director of the Foundation, noted. It was exciting to see people interested in the Foundation's mission and what it represents.



MCRF Staff Members
Pictured Above
Pictured left to right: Jeannette Byrd, Laura Gayton, Penny Stoakes, Maureen Koepke, Jan Harper, Gail Shammas, and Denise Coiner

Visitors enjoyed the great food, wine and decorations of MCRF's office that were put together by MCRF staff (pictured left). Visitors toured the office and got acquainted with various aspects of MCRF's functions including its research, education and administrative sections. They got acquainted with the various programs that the Foundation did this year including various publications, educational programs and the research students program.

This year MCRF staff were busy with the upcoming new book "Live Long, Live Healthier. The Secrets for Graceful Aging" expected to be published the end of February 2007. Also, MCRF investigators has published over 14 manuscripts and abstracts in 2006 and 2 chapters in national books. Over 15 national clinical trials and several investigator-initiated studies have also been conducted and two point-counterpoint conferences and MCRF's annual conference CIPG 2006 were a great success.




In This Issue...

MCRF's Holiday Open House	1
Clinical Trials.....	2
New Cardiovascular Horizons Conference	3
CIPG 2006 Conference Recap.....	4
Industry Appreciation	5
Publications Carrying MCRF Name	6

Clinical Trials

The following clinical trials are on-going at MCRF:

- ♥ **CELLO:** (Tentative) CLiRpath® Excimer Laser System to Enlarge Lumen Openings....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Denise Coiner, RTR, Contact Phone Number: 563-324-4384, Sponsor: Spectranetics
- ♥ **COSTAR:** Cobalt chromium STent with Antiproliferative for Restenosis II Trial....CLOSED, Direct Stenting will start in February 2007. Principal Investigator: Nicolas W. Shammam, MD, Clinical Coordinator: Denise Coiner, RTR, Contact Phone Number: 563-324-4384, Sponsor: Conor Medsystems
- ♥ **CRESCENDO:** Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO).... Principal Investigator: Brian Anseeuw, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Sanofi-Aventis
- ♥ **DETHROMBOSIS:** Dethrombosis of the lower extremities using the Power-Pulse Spray technique: Validation of a prospective algorithm....Principal Investigator: Nicolas W. Shammam, MD, Clinical Coordinator: Laura Gayton, RN, Contact Phone Number: 563-324-4384, Sponsor: Midwest Cardiovascular Research Foundation
- ♥ **DORADO:** Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension....Principal Investigator: Nicolas W. Shammam, MD, Clinical Coordinator: Nicolas W. Shammam, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Myogen, Inc.
- ♥ **EXACT:** Emboshield and Xact Post Approval Carotid Stent Trial using the Emboshield® Bare Wire™ Rapid Exchange Embolic and Xact® Rapid Exchange Carotid Stent System ...Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular Devices
- ♥ **FUSION II:** Follow-up serial infusions of Natreacor® (nesiritide) for the management of patients with heart failure.... CLOSED To ENROLLMENT. Principal Investigator: Nicolas Shammam, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Scios
- ♥ **IMPROVE IT:** A multi-center, double-blind randomized study to establish the clinical benefit and safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in high-risk subjects presenting with acute coronary syndrome (IMPROVED Reduction of Outcomes: Vytorin EffiCaCY International.....
 - ♥ Improve It Continued....Principal Investigator: Nicolas W. Shammam, MD, Clinical Coordinator: Denise Coiner, RTR, Contact Phone Number: 563-324-4384, Sponsor: Schering-Plough
 - ♥ **MEND-CABG II:** A Phase III, randomized, double blind, placebo controlled, multi-center study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft (CABG) surgery...Principal Investigator: Nicolas W. Shammam, MD, Clinical Coordinator: Laura Gayton, RN, Contact Phone Number: 563-324-4384, Sponsor: Medicure International Inc.
 - ♥ **RESIST:** A prospective, randomized, multi-center study comparing the safety and efficacy of Renal Artery Stenting with and without the use of a Distal Protection Device (AngioGuard) and with and without the use of a Platelet Aggregator Inhibitor (Abciximab)....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Cordis
 - ♥ **TRITON:** A comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI 38....Principal Investigator: Nicolas W. Shammam, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Eli Lilly and Company.
 - ♥ **VIVA I XCELL:** VIVA I: XCELL Trial XPERT™ NITINOL STENTING FOR CRITICALLY ISCHEMIC LOWER LIMBS....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: VIVA Physicians, Inc.
 - ♥ **ZoMAXX:** A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx™ Drug Eluting Coronary Stent System as Compared to TAXUS™ Express²™ Paclitaxel-Eluting Stent in *de novo* Coronary Artery Lesions....Principal Investigator: Nicolas W. Shammam, MD, Clinical Coordinator: Denise Coiner, RTR, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular Devices




Upcoming Trials

Trials coming soon to MCRF:

- ♥ SFA (Superficial Femoral Artery)...Principal Investigator: Eric Dippel, MD, Sponsor: Cordis
- ♥ STEALTH II...Principal Investigator: Eric Dippel, MD, Sponsor: Biosensors International USA
- ♥ LEAP...Principal Investigator: Eric Dippel, MD, Sponsor: Fox Hollow — ON HOLD
- ♥ TRA PCI...Principal Investigator: Peter Sharis, MD, Contact Phone Number: 563-324-4384, Sponsor: Schering-Plough



Pictured Below: Eric J. Dippel, MD
Associate Research Director
Midwest Cardiovascular Research Foundation



Pictured Above: Nicolas W. Shammam, MD
President and Research Director
Midwest Cardiovascular Research Foundation

Investigator Initiated Protocols

- ♥ A Randomized Trial of Percutaneous Transluminal Angioplasty versus Atherectomy Using the Silverhawk Foxhollow Catheter. The Principal Investigator is Dr. Nicolas W. Shammam, MS, MD the Co-Investigators are Eric Dippel, MD. The study coordination is through Midwest Cardiovascular Research Foundation.
- ♥ In-hospital complications and 9 months follow-up of patients receiving bifurcating taxus drug eluting stents: a real life experience from a busy single center interventional laboratory. The Principal Investigator is Dr. Nicolas W. Shammam, MS, MD. The study coordination is through Midwest Cardiovascular Research Foundation.
- ♥ Interatrial Septal Defect Closure For Cerebrovascular Accidents: Impact on Recurrence and Frequency of Migraine Headaches. The principal Investigator is Dr. Nicolas W. Shammam, MS, MD. The study coordination is through Midwest Cardiovascular Research Foundation.
- ♥ Preprocedural C-Reactive Protein, Lp(a), homocysteine and fibrinogen levels predict death, myocardial infarction and graft disease after coronary artery bypass surgery. The principal Investigator is Dr. Nicolas W. Shammam, MS, MD. The study coordination is through Midwest Cardiovascular Research Foundation.



Acuity Trial Update

Below is the conclusions from a recent published article on the Acuity Trial that Dr. Nicolas Shammam, MD and Dr. Eric Dippel, MD had participated in.

Conclusions from Acuity Trial: In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin. Bivalirudin alone was associated with similar rates of ischemia and significantly lower rates of bleeding. (Clinical Trials.gov number, NCT00093158 [ClinicalTrials.gov].)



To view this article please log on to this link: <http://content.nejm.org/cgi/content/short/355/21/2203>



Cardiovascular Interventions and Practice Guidelines 2006 Conference


Cardiovascular Interventions and Practice Guidelines (CIPG) 2006 is the annual conference of MCRF. This year it was held at the Adler Theater, Genesis Heart Institute. Over 125 people attended this conference that included the following 18 speakers:

- ♥ Nicolas W. Shammam, MS, MD (conference Director)
- ♥ Eric J. Dippel, MD (conference Co-Director)
- ♥ Peter P. Toth, MD, PhD
- ♥ Helbert Acosta MD
- ♥ Richard Sadler, MD
- ♥ Catherine Weideman, MD
- ♥ Matthew Wilber, DP
- ♥ Sanjeev Puri, MD
- ♥ Rafaat Padaria, MD
- ♥ Mark Kovach, MD
- ♥ Akshay Mahadevia, MD
- ♥ Nical Harb, MD
- ♥ Vijay Rajendran, MD
- ♥ Blair Foreman, MD
- ♥ Humphrey Wong, MD
- ♥ Peter Sharis, MD
- ♥ Karen Doy
- ♥ Walid Al-Sheika, MD




CIPG 2006 covered a variety of topics related to cardiopulmonary disease and was a true multidisciplinary conference with speakers and attendees from various specialties in medicine and surgery. Among the topics covered was aortic dissection and aneurysm, management of carotid disease, renovascular hypertension and its management, emerging techniques in dethrombosing lower extremity vessels and wound management in chronic limb ischemia, different methodology in risk stratifying a cardiac patient, management of unstable angina,

NSTEMI and STEMI, cardiovascular risk factors including low HDL syndrome, diabetes and hypertension and their management, exercise for the cardiac patient, biventricular pacing for congestive heart failure, management of atrial fibrillation patent foramen ovale in cryptogenic strokes and its management, sleep apnea, pulmonary hypertension and valvular heart disease and its management.



On Friday evening a reception with live music was held and participants enjoyed good food catered by the Faithful Pilot and wine.

CIPG 2007 will also be held at the Adler Theater in the Genesis Heart Institute, Genesis east campus. A live case from the Cardiac catheterization laboratory will be performed to the audience on Friday afternoon which will focus predominantly on peripheral vascular disease. CIPG 2007 will be free to all registrants. Space will be limited, though to the first 60 physician and registrants and 140 allied health care attendees. Check our website www.mcrfmd.com for upcoming information about registration.



MCRF Board of Directors
 Pictured left to right: Dr. Eric Dippel, MD, Dr. Nicolas W. Shammam, MD, and Dr. Peter P. Toth, PhD.

Industry Sponsor Appreciation



- Abbott Laboratory
- AstraZeneca LP
- Boston Scientific Corporation
- Bristol-Myers Squibb Company
- Cordis Corporation
- GE Medical
- Guidant
- KOS Pharmaceutical
- Eli Lilly and Company
- The Medicines Company
- Medtronic
- Sanofi-Aventis
- Schering-Plough Corporation
- Scios, Inc.
- Spectranetics
- St. Jude's Medical
- Wyeth Pharmaceuticals

New Cardiovascular Horizons Conference

Dr Nicolas Shammass presented several lectures at New Cardiovascular Horizons in New Orleans, Nov 1-4 and moderated live cases from the Cardiovascular Institute of the South (CIS).

In the Critical Limb Ischemia conference, Dr Shammass spoke on "Endopharmacotherapeutic interventions in CLI" and moderated a CLI case from CIS. In the Primary Cardiovascular conference, he lectured on : "Predicting the High Risk Cardiovascular patient. Biomarkers, calcium Scoring and the Future" and "Medical Therapy and Cardiovascular Disease: what Drugs really save Lives?". Furthermore, in the Comprehensive Nursing Symposium Dr Shammass discussed "The management of the Diabetic Hypertensive patient". Finally, Dr Shammass recorded a web conference with Dr David Allie, the chair of the conference, on "Dethrombosis of the lower extremity vessels" which will be presented on the web on November 17 by HMP communications.

During the same meeting Dr Shammass presented three abstracts from research performed by the Midwest Cardiovascular Research Foundation investigators (posters can be viewed on our website under the "News Room" section.

Shammass NW, Dippel EJ, Harb G, Egts S, Jerin M, Stoakes P, Byrd J, Sharis P. Interatrial Septal Defect Closure For Cerebrovascular Accidents: Impace on Intensity and Frequency of Migraine Headaches. Presented at New Cardiovascular Horizons 2006, New Orleans, LA. November 1-4, 2006.

Shammass NW, Dippel EJ, Harb G, Egts S, Jerin M, Stoakes P, Byrd J, Sharis P. Interatrial Septal Defect Closure For Cerebrovascular Accidents: The Role of the Intraprodecural Use of Bivalirudin. Presented at New Cardiovascular Horizons 2006, New Orleans, LA. November 1-4, 2006.

Shammass NW, Dippel EJ, Wisdon A, Gehbauer L, Farland L, Brosius S, Jerin M, Winter M, Stoakes P, Byrd J, Majetic L, Sharis P, Robken J. Long Term Outcome in Treating Trifurcation Coronary Artery Disease with the Taxus Drug Eluting Stent. Presented at New Cardiovascular Horizons 2006, New Orleans, LA. November 1-4, 2006.



Recent Publications Carrying MCRF Name

- ♥ Shammas NW, Lemke JH, Deckert J, Toth PP, McKinney D, Dippel EJ. Gender differences in adhering to national guidelines in a community lipid clinic. *Prev Cardiol.* 2006 Fall; 9(4):215-8
- ♥ Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazziha S, Rokos I, Shammas NW, Palabrica TM, Fish P, McCabe CH, Braunwald E; TIMI Study Group. Early initiation of eptifibatid in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. *AmHeart J.* 2006 Oct;152(4):668-75. This manuscript was published with the Harvard group.
- ♥ Shammas NW, Kapalis MJ, Kirchner HL, Lemke JH, Hauber W, Dippel EF. Defect Size on Sestamibi Stress Testing Does Not Predict High Sensitive C—Reactive Protein in Patients with Coronary Artery Disease. *International Journal of Angiology*, 2006 (in print).
- ♥ Shammas NW. Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. In Gotto and Toth, *Prevention of High Risk Cardiovascular Disease.* Taylor and Francis, 2006, pages 529-542.
- ♥ Shammas NW, Dippel EJ, Amidon C, Patel P, Ancheta G, Ratnakar S, Harb H. In-Hospital Complications in Treating Chronic Limb Ischemia: The Feasibility of Alternative Anticoagulation Therapy to Unfractionated Heparin. *Vascular Disease Management* 2006;3:328-330.
- ♥ Dippel EJ, Shammas NW, Takes VS, Coyne LE, Lemke JH. Twelve-Month Results of Percutaneous Endovascular Reconstruction for Chronically Occluded Superficial Arteries: A Quality of Life Assessment. *J Invasive Cardiol*, 2006;18 (6):316-321.
- ♥ Shammas NW. Dethrombosis of the Lower Extremities: Pharmacologic and mechanical Techniques. *Vascular Disease Management*, May/June, 2006.

TO CONTACT MCRF.....


Feel free to contact us regarding submitting manuscripts or articles, obtaining publications, booking a speaker, contributing funds or other matters.

To submit manuscripts, discuss research possibilities, etc., contact:

Dr. Nicolas W. Shammas, MD
 President & Research Director
 Editor-in-Chief, Editorial Board
shammas@mchsi.com

For other assistance or information, contact:

Maureen Koepke
 Office Manager
 563.324.2828
koepkem@mcrfmd.com



We're On The Web!
www.mcrfmd.com

Midwest Cardiovascular Research Foundation

1622 E. Lombard Street
 Davenport, IA 52803

Phone: 563.324.2828
 Fax: 563.324.2835